SPECIAL REPORT

7^TH JOINT ECTRIMS-ACTRIMS MEETING – October 25-28, 2017

Teriflunomide
Dimethyl fumarate
Fingolimod
Alemtuzumab Read More

Health Canada has approved cladribine tablets for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS), to reduce the frequency of clinical exacerbations and delay the progression of disability. The drug, marketed as Mavenclad, may be used for newly-diagnosed patients, but is generally recommended in MS patients with an inadequate response or poor tolerability to a prior MS therapy. Read More

Cladribine tablets, a novel intermittent immunosuppressant expected soon in North America, has been shown to be highly efficacious in reducing annualized relapse rates (ARR) and disability progression over a sustained period, according to the most recent data. Read More

Thursday Edition
Friday Edition

Head-to-head (to head) studies
Switching/sequencing studies
New analyses of DMT effectiveness
Use of gadolinium – consensus statement
Pregnancy rate on the increase in women with MS Read More